Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

Next Previous
X
Search
Trial Profile

Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temelimab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors GeNeuro

    • Most Recent Events

    • 03 Sep 2014 Results published in the Media Release.
    • 14 Mar 2014 On 4 Nov 2013, GeNeuro reported the trial is completed however, ClinicalTrials.gov record was updated on 27 Jan 2014 to report the status as active, no longer recruiting with an estimated primary completion date of Feb 2014.
    • 04 Nov 2013 Top-line results reported in a GeNeuro media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top